INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network
19 Mar 2024 - Torque Metals Limited (ASX:TOR) Managing Director Cristian Moreno discusses the roadmap for the company and promising recent results.
Read More14 Mar 2024 - Delve into the cutting-edge realm of regenerative medicine with Kilian Kelly, CEO of Cynata Therapeutics. Learn how their stem cell innovations are shaping the future of healthcare.
Read More01 Mar 2023 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt discusses data from SITC, the strategy to take Efti to market and milestones for 2023.
Read More13 Sep 2022 - Imdex Limited (ASX:IMD) CEO Paul House discusses FY22 financial and operational highlights, the first commercial contract for Blast Dog, growth opportunities and outlook.
Read More29 Jul 2022 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent key announcements, including the appointment of a US sales team, the securing of a US patent, quarterly results, and the year ahead.
Read More27 Nov 2023 - Enlitic CEO Michael Sistenich discusses the company's AI solutions for healthcare data management as the company gears up for its December IPO.
Read More02 Oct 2024 - Lithium Universe Limited (ASX:LU7) CEO Alex Hanly discusses the company's prefeasibility study, operational costs and development timeline.
Read More23 Oct 2019 - Cashwerkz Limited (ASX:CWZ) Executive Director, Craig Swanger talks about the company's platform, the benefit it provides for both banks and investors, FY19 results and outlook.
Read More13 May 2025 - Mission-critical communications with global expansion potential.
Read More12 May 2025 - Phil Smith, a Director at AL Capital, discusses the company's strategy and focus on capital protection.
Read More
